Medication info
Nexgliptin Tablet 100 mg (Sitagliptin Hydrochloride Monohydrate)

Nexgliptin Tablet 100 mg (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.4mg / 1 tablet
Manufacturer / importer
Bionex Co., Ltd.
Appearance
Light orange, round, biconvex film-coated tablets
Packaging
30 tablets - 10 tablets/PTP[x3]
Approval status
Active

MFDS item code 202005610 · Approved 2020.08.03 · Insurance code 643105710

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
Whether used as monotherapy or in combination therapy, administer 100 mg once daily; the maximum daily dose is 100 mg. This medication may be taken with or without food. When administered in combination with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). Patients with renal impairment Dose adjustment according to renal function is necessary; therefore, assessment of renal function is recommended before treatment with this medication and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medication may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Bionex Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used in conjunction with diet and exercise to help control blood sugar in patients with type 2 diabetes. It is administered alone for patients who are beginning treatment, and if blood sugar control is difficult with monotherapy alone, it is combined with metformin. Furthermore, in cases where blood sugar control is insufficient with monotherapy or combined therapy of sulfonylureas, metformin, thiazolidinediones, insulin, etc., this medication is added to enhance the therapeutic effect. It is used to improve blood sugar control through various treatment methods and combinations.

How to take

Adult dose

Whether used as monotherapy or in combination therapy, administer 100 mg once daily; the maximum daily dose is 100 mg. This medication may be taken with or without food. When administered in combination with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). Patients with renal impairment Dose adjustment according to renal function is necessary; therefore, assessment of renal function is recommended before treatment with this medication and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medication may be administered regardless of the timing of dialysis.

Precautions

This medication can occasionally cause serious allergic reactions, so if symptoms such as skin rash or difficulty breathing occur, stop taking it immediately and consult a physician. Additionally, if symptoms of pancreatitis such as severe abdominal pain, vomiting, or fever develop while taking this medication, seek medical attention immediately. Patients with type 1 diabetes or a history of allergic reactions to this medication should not use it. Patients with renal impairment need to adjust the dosage of this medication, so they should take it according to their physician's instructions. While taking this medication, symptoms of hypoglycemia may occur, especially if taken in conjunction with insulin or sulfonylureas, so caution is advised. If severe joint pain or symptoms of skin blistering occur, notify a physician immediately and discontinue use of the medication. Pregnant or breastfeeding women are advised not to take this medication, and safety in children under 18 years has not been established. Elderly patients should undergo regular kidney function tests because renal function may be decreased during use. In case of overdose, gastrointestinal decontamination and appropriate treatment such as ECG monitoring should be applied, and some drugs may be removed by hemodialysis. This medication may interact with other diabetes treatments or specific medications, so inform your physician or pharmacist about any other medications you are taking. It is important to consult medical personnel immediately if any abnormal symptoms occur.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • upper respiratory tract infection
  • pharyngitis
  • headache
  • diarrhea
  • abdominal pain
Show 31 more
  • nausea
  • constipation
  • vomiting
  • rash
  • urticaria
  • cutaneous vasculitis
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • pneumonia
  • diabetic complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased blood triglycerides
  • gastritis
  • severe hypoglycemia
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container that is well-ventilated and kept at room temperature between 1 and 30 degrees Celsius. Storing it this way helps to maintain the medication’s efficacy over time.

Appearance and packaging

Appearance

Light orange, round, biconvex film-coated tablets

Package unit

30 tablets - 10 tablets/PTP[x3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.